Cystadenocarcinoma
| Ovarian Cystadenocarcinoma | |
|---|---|
| Other names | cystadenoma carcinoma |
| Intermediate magnification micrograph of a low malignant potential (LMP) mucinous ovarian tumour. H&E stain.
The micrograph shows: Simple mucinous epithelium (right) and mucinous epithelium that pseudo-stratifies (left - diagnostic of a LMP tumour). Epithelium in a frond-like architecture is seen at the top of image. | |
| Specialty | Gynaecological oncology |
| Symptoms | Abdominal pain, Abdominal swelling/distension, Increased abdominal girth, Bloating, ascites, nausea, Vomitting, Unusual Bowel and bladder movement, lack of appetite/early satiety, weightloss, fatigue, vaginal bleeding, acid reflux, shortness of breath |
| Differential diagnosis | ovarian cyst, uterine fibroid, benign uterine lesions, pelvic abscess, pelvic inflammatory disease, adnexal tumours, endometriosis, distended bladder, impacted faecal matter, tumour of appendix, uterine anomalies, hydro/pyosalpinx, adhesions of bowel or momentum, carcinoma of colon, embryonic adhesions, tracheal cyst, adenocarcinoma of stomach, low-lying caecum, metastasised gastrointestinal carcinoma, ovarian torsion, pelvic kidney, peritoneal cyst, retroperitoneal mass, irritable bowel syndrome. |
| Treatment | surgical debunking surgery with or without chemotherapy |
| Medication | carboplatin, paclitaxel, cisplatin, Liposomal doxorubicin, etoposide, topotecan, gemcitabine, docetaxel, vinorelbine, ifosfamide, fluorouracil, melphalan, altretamine, bevacizumab, olaparib, rucaparib, niraparib, mesna. |
Cystadenocarcinoma is a malignant tumor that arises from glandular epithelial cells and forms cystic structures. It is most commonly found in the ovaries and pancreas, but it can also develop in other organs. The exact cause of cystadenocarcinoma is not well understood, though genetic predisposition, chronic inflammation, and hormonal influences are thought to contribute to its development. The frequency of cystadenocarcinoma varies by type; for example, ovarian cystadenocarcinomas account for a significant proportion of ovarian cancers.